Determining Triglyceride Reductions Needed for Clinical Impact in Severe Hypertriglyceridemia Jennifer B. Christian, PharmD, MPH, PhD, Bhakti Arondekar, BPharm, MBA, PhD, Erin K. Buysman, MS, Terry A. Jacobson, MD, Rose G. Snipes, MD, Ralph I. Horwitz, MD The American Journal of Medicine Volume 127, Issue 1, Pages 36-44.e1 (January 2014) DOI: 10.1016/j.amjmed.2013.09.018 Copyright © 2014 Elsevier Inc. Terms and Conditions
Figure 1 Patient selection. The American Journal of Medicine 2014 127, 36-44.e1DOI: (10.1016/j.amjmed.2013.09.018) Copyright © 2014 Elsevier Inc. Terms and Conditions
Figure 2 Laboratory results stratified by follow-up triglyceride level (mg/dL). The American Journal of Medicine 2014 127, 36-44.e1DOI: (10.1016/j.amjmed.2013.09.018) Copyright © 2014 Elsevier Inc. Terms and Conditions
Figure 3 Crude incidence rates (per 100 person-years) for clinical events in the follow-up period stratified by follow-up triglyceride level (mg/dL). The American Journal of Medicine 2014 127, 36-44.e1DOI: (10.1016/j.amjmed.2013.09.018) Copyright © 2014 Elsevier Inc. Terms and Conditions
Figure 4 Adjusted IRRs* for clinical events in the follow-up period stratified by follow-up triglyceride level (mg/dL). Reference group is follow-up triglyceride levels ≥500 mg/dL. The American Journal of Medicine 2014 127, 36-44.e1DOI: (10.1016/j.amjmed.2013.09.018) Copyright © 2014 Elsevier Inc. Terms and Conditions